Macitentan, a new drug, has been registered
Mir-Pharm announces successful registration of new orphan drug
Moscow, September 2023
Macitentan belongs to the group of antihypertensive agents, which are used in pulmonary arterial hypertension (PAH - increased pressure in the blood vessels leading from the heart to the lungs) and are used for its long-term treatment.
Mode of action of the drug Macitentan
The drug Macitentan contains the active ingredient - macitentan, which is an antagonist of endothelin receptors, which in turn contributes to vasoconstriction. Macitentan permanently blocks endothelin-1 receptors of smooth muscle cells of pulmonary arteries and prevents pressure increase in the pulmonary artery.
Note:
The press release contains information about prescription medications. Use of this information for preparation of publications must be made in accordance with the legislation of the Russian Federation on advertising (including but not limited to Art. 24 of the Federal Law of 13.03.2006 No. 38-FL "On Advertising"), according to which, in particular, advertising of prescription drugs is allowed only in places of medical or pharmaceutical exhibitions, workshops, conferences and other similar events as well as in specialized print media intended for medical and pharmaceutical workers. Failure to comply with the above requirements (namely, mentioning the name of the drug, placing an image of the package or its elements in the media other than specialized print publications intended for medical and pharmaceutical workers) shall entail administrative liability.